Agios Pharmaceuticals, Inc. insider trading
Every open-market purchase and sale by Agios Pharmaceuticals, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Agios Pharmaceuticals, Inc.’s insiders pay?
From April 30, 2014 to March 5, 2026, 14 insiders reported 11 open-market purchases and 21 sales not made under a pre-set plan in Agios Pharmaceuticals, Inc. Twelve months after each purchase was reported, the shares were +19.4% against the S&P 500 on average (median −8.2%), over 11 purchases with a full year of prices; 36% beat the index. After sales, the shares moved −6.6% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on May 1, 2014 into $26,851 by November 2, 2026, +8.2% a year. It held shares 36% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $19,934 (+5.7% a year), and held throughout $49,484 (+13.7%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Washburn Theodore James JR. | Principal Accounting Officer | 0 | — | — | 7 | −12.3% (6) | March 5, 2026 |
| Maraganore John | Director | 3 | +63.2% (3) | 67% | 1 | −55.7% (1) | September 13, 2018 |
| Foster-Cheek Kaye I | Director | 0 | — | — | 3 | +7.5% (3) | March 11, 2024 |
| Nelsen Robert | Director | 0 | — | — | 3 | +47.0% (3) | March 7, 2017 |
| Schenkein David P | Director | 1 | −8.2% (1) | 0% | 2 | −14.2% (2) | February 29, 2024 |
| Celgene Corp /de/ | 10% owner | 2 | +14.1% (2) | 50% | 0 | — | January 23, 2018 |
| Celgene European Investment Co LLC | 10% owner | 2 | +25.9% (2) | 50% | 0 | — | December 17, 2014 |
| Miles Darrin | Chief Commercial Officer | 0 | — | — | 2 | −57.9% (2) | May 18, 2021 |
| Alenson Carman | Principal Accounting Officer | 0 | — | — | 1 | −27.9% (1) | February 20, 2019 |
| Burns James William | Chief Legal Officer | 0 | — | — | 1 | +40.3% (1) | August 21, 2023 |
| Celgene Alpine Investment Co., LLC | 10% owner | 1 | −6.7% (1) | 0% | 0 | — | November 14, 2019 |
| Fouse Jacqualyn A | Chief Executive Officer | 1 | −8.2% (1) | 0% | 0 | — | November 15, 2019 |
| Hoerter Steven L. | Chief Commercial Officer | 0 | — | — | 1 | −34.2% (1) | March 5, 2019 |
| Scadden David | Director | 1 | −33.3% (1) | 0% | 0 | — | March 20, 2018 |
When several insiders traded Agios Pharmaceuticals, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Agios Pharmaceuticals, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 4 buying crowds with six months of prices, it averaged +49.1% against the index. After 2 selling crowds, +24.4%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| March 28, 2024 | 3 selling | +43.1% | +46.0% | −14.9% |
| August 31, 2023 | 3 selling | −20.7% | +2.7% | +38.8% |
| November 29, 2019 | 3 buying | +24.3% | +35.3% | +1.7% |
| March 29, 2018 | 2 buying | −2.1% | −18.4% | −31.9% |
| December 31, 2014 | 2 buying | −16.7% | −3.2% | −43.3% |
| May 30, 2014 | 2 buying | +23.6% | +182.6% | +235.7% |